

V. Reference

- Abate C, Luk D, Curran T. 1991. Transcriptional regulation by Fos and Jun in vitro: interaction among multiple activator and regulatory domains. *Mol Cell Biol* 11:3624-3632.
- Albiero R, Adamian M, Kobayashi N, Amato A, Vaghetti M, Di Mario C, Colombo A. 2000. Short- and intermediate-term results of ^{32}P radioactive β -emitting stent implantation in patients with coronary artery disease: the Milan dose-response study. *Circulation* 101:18-26.
- Allavena P, Paganin C, Martin-Padura I, Peri G, Gaboli M, Dejana E, Marchisio PC, Mantovani A. 1991. Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. *J Exp Med* 173:439-448.
- Ambrose JA, Barua RS. 2004. The pathophysiology of cigarette smoking and CVD; an update. *J Am Coll Cardiol* 43:1731-1737.
- Anderson AJ, Pike CJ, Cotman CW. 1995. Differential induction of immediate early gene proteins in cultured neurons by β -amyloid ($\text{A } \beta$): association of c-Jun with $\text{A } \beta$ -induced apoptosis. *J Neurochem* 65:1487-1498.
- Anonymous. 1992. Does the new ACE inhibitor cilazapril prevent restenosis after PTCA? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. *Circulation* 86:100-110.
- Astin F, Jones K. 2004. Heart disease attributions of patients prior to elective PTCA. *J Cardiovasc Nurs* 19:41-47.
- Autieri MV. 1996. cDNA cloning of human AIF-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. *Biochem Biophys Res Commun* 228:29-37.

- Autieri MV, Carbone C, Mu A. 2000. Expression of AIF-1 is a marker of activated human VSMCs and arterial injury. *Arterioscler Thromb Vasc Biol* 20:1737-1744.
- Autieri MV. 2002. The role of AIF-1 in development of coronary artery vasculopathy. *Drug News Perspect* 15:498-505.
- Autieri MV, Kelemen SE, Wendt KW. 2003. AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes VSMC migration. *Circ Res* 92:1107-1114.
- Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. 1997. Paclitaxel inhibits arterial SMC proliferation and migration in vitro and in vivo using local delivery drug. *Circulation* 96:636-645.
- Axon Instruments. GenePix Pro 4.0 User's Guide and Tutorial.
- Baeuerle PA, Henkel T. 1994. Function and activation of NF- κ B in the immune system. *Annu Rev Immunol* 12:141-179.
- Baeuerle PA, Baltimore D. 1996. NF- κ B: ten years after. *Cell* 87:13-20.
- Bobryshev YV, Lord RS, Rainer SP, Munro VF. 1996. VCAM-1 expression and network of VCAM-1 positive vascular dendritic cells in advanced atherosclerotic lesions of carotid arteries and aortas. *Acta Histochem* 98:185-194.
- Bochner BS, Luscincas FW, Gimbrone MA Jr, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP. 1991. Adhesion of human basophils, eosinophils and neutrophils to IL-1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. *J Exp Med* 173:1553-1557.
- Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. 1996. Activated transcription factor NF- κ B is present in the atherosclerotic lesion. *J Clin Invest* 97:1715-1722.
- Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. 2002. Activation of NF- κ B

- significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 105:633-638.
- Campbell KJ, Rocha S, Perkins ND. 2004. Active repression of antiapoptotic gene expression by RelA (p65) NF- κ B. Mol Cell 13:853-865.
- Campeau L, Lesperance J, Hermann J, Corbara F, Grondin CM, Bourassa MG. 1979. Loss of improvement of angina between 1 and 7 years after aortocoronary bypass surgery. Circulation 60:1-5.
- Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M. 1990. VCAM-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76:965-970.
- Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. 1994. Morphologic characteristics of lesion formation and time course of SMC proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 24:1398-1405.
- Carter AJ, Scott D, Bailey L, Hoopes T, Jones R, Virmani R. 1999. Dose-response effects of ^{32}P radioactive stents in an atherosclerotic porcine coronary model. Circulation 100:1548-1554.
- Casterella PJ, Teirstein PS. 1999. Prevention of coronary restenosis. Cardiol Rev 7:219-231.
- Chen X, Kelemen SE, Autieri MV. 2004. AIF-1 expression modulates proliferation of human VSMCs by autocrine expression of G-CSF. Arterioscler Thromb Vasc Biol 24:1217-1222.
- Collins T. 1993. Endothelial NF- κ B and the initiation of the atherosclerotic lesion. Lab Invest 68:499-508.
- Collins TC, Beyth RJ. 2003. Process of care and outcomes in peripheral arterial disease. Am J Med Sci 325:125-134.
- Condado JA, Waksman R, Gurdiel O, Espinosa R, Gonzalez, J, Burger B, Villoria G,

Acquatella H, Crocker IR, Seung KB, Liprie SF. 1997. Long-term angiographic and clinical outcome after PTCA and intracoronary angioplasty in humans. *Circulation* 96:727-732.

Costa MA, Sabat M, van der Giessen WJ, Kay IP, Cervinka P, Lighthart JM, Serrano P, Coen VL, Levendag PC, Serruys PW. 1999. Late coronary occlusion after intracoronary brachytherapy. *Circulation* 100:789-792.

Cramer P, Larson CJ, Verdine GL, Muller CW. 1997. Structure of the human NF- κ B p52 homodimer-DNA complex at 2.1 Å resolution. *EMBO J* 23:7078-7090.

Cybulsky MI, Gimbrone MA Jr. 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* 251:788-791.

Dalton TP, Li Q, Bittel D, Liang L, Andrews GK. 1996. Oxidative stress activates metal-responsive transcription factor-1 binding activity. Occupancy in vivo of metal response elements in the metallothionein-I gene promoter. *J Biol Chem* 271:26233-29241.

Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. 1993. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. *J Pathol* 171:223-229.

de Waard V, van den Berg BM, Veken J, Schultz-Heienbrok R, Pannekoek H, van Zonneveld AJ. 1999. Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. *Gene* 226:1-8.

Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ. 2002. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to two years) clinical, angiographic, and IVUS follow-up. *Circulation* 106:1610-1613.

Department of Health, Executive Yuan, Taiwan, R.O.C., Statistics & Analysis: National Health Insurance 2000.

Duan H, Tsvetkov LM, Liu Y, Song Y, Swaroop M, Wen R, Kung HF, Zhang H, Sun Y. 2001. Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation. *Mol Carcinog* 30:37-46.

Dynan WS, Tjian R. 1983. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. *Cell* 35:79-87.

Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. *Cell* 60:577-584.

Emanuelsson H, Beatt KJ, Bagger JP, Balcon R, Heikkila J, Piessens J, Schaeffer M, Suryapranata H, Foegh M. 1995. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. *Circulation* 91:1689-1696.

Fan CM, Maniatis T. 1991. Generation of p50 subunit of NF- κ B by processing of p105 through an ATP-dependent pathway. *Nature* 354:395-398.

Farb A, Shroff S, John M, Sweet W, Virmani R. 2001. Late arterial responses (6 and 12 months) after ^{32}P β -emitting stent placement: sustained intimal suppression with incomplete healing. *Circulation* 103:1912-1919.

Feng Y, Yang JH, Huang H, Kennedy SP, Turi TG, Thompson JF, Libby P, Lee RT. 1999. Transcriptional profile of mechanically induced genes in human VSMCs. *Circ Res* 85:1118-1123.

Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. 1994. A randomized comparison of coronary stent placement and balloon

- angioplasty in the treatment of coronary artery disease. *N Engl J Med* 331:496-501.
- Foley DP, Serruys PW. 1996. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty; angiographic and methodological background of the fluvastatin angioplasty restenosis trial. *Br J Clin Pract (Suppl)* 77A:40-53.
- Freedman AS, Munro JM, Rice GE, Bevilacqua MP, Morimoto C, McIntyre BW, Rhynhart K, Pober JS, Nadler LM. 1990. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. *Science* 249:1030-1033.
- Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW. 2000. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. *Proc Natl Acad Sci USA* 97:14352-14357.
- Ghosh G, van Duyne G, Ghosh S, Sigler PB. 1995. Structure of NF- κ B p50 homodimer bound to a κ B site. *Nature* 373:303-310.
- Ghosh S, May MJ, Kopp EB. 1998. NF- κ B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol* 16:225-260.
- Gibbs JS, McCoy AS, Gibbs LM, Rogers AE, Addington-Hall JM. 2002. Living with and dying from heart failure: the role of palliative care. *Heart* 88 (Suppl 2):ii36-39.
- Gibbs JL, Monro JL, Cunningham D, Rickards A; Society of Cardiothoracic Surgeons of Great Britain and Northern Ireland; Paediatric Cardiac Association; Alder Hey Hospital. 2004. Survival after surgery or therapeutic catheterization for congenital heart disease in children in the UK: analysis of the central cardiac audit database for 2000-1. *BMJ* 328:611-615.
- Gillardon F, Eschenfelder C, Uhlmann E, Hartschuh W, Zimmermann M. 1994. Differential regulation of c-Fos, FosB, c-Jun, JunB, bcl-2 and bax expression in rat skin following single or chronic ultraviolet irradiation and in vivo modulation by antisense ODN superfusion. *Oncogene* 9:3219-3230.

- Grant MB, Wargovich TJ, Ellis EA, Tarnuzzer R, Caballero S, Estes K, Rossing M, Spoerri PE, Pepine C. 1996. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. *Regul Pept* 67:137-144.
- Graves BJ, Johnson PF, McKnight SL. 1986. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. *Cell* 44:565-576.
- Greuntzig AR, Senning A, Siegenthaler WA. 1979. Nonoperative dilatation of coronary artery stenosis: PTCA. *N Engl J Med* 301:61-68.
- Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. 2003. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. *Circulation* 107:38-42.
- Gruda MC, Kovary K, Metz R, Bravo R. 1994. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAPK affects DNA binding activity. *Oncogene* 9:2537-2547.
- Gruntzig A. 1978. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263.
- Gum R, Wang H, Lengyel E, Juarez J, Boyd D. 1997. Regulation of 92 kDa type IV collagenase expression by the Jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. *Oncogene* 14:1481-1493.
- Hallahan DE, Dunphy E, Virudachalam S, Sukhatme VP, Kufe DW, Weichselbaum RR. 1995. c-Jun and Egr-1 participate in DNA synthesis and cell survival in response to IR exposure. *J Biol Chem* 270:30303-30309.
- Hill CS, Wynne J, Treisman R. 1994. Serum-regulated transcription by serum response factor -a novel role for the DNA binding domain. *EMBO J* 13:5421-5432.
- Hoberg E, Kubler W. 1991. Prevention of restenosis after PTCA: role of calcium antagonists. *J Cardiovasc Pharmacol (Suppl)* 18:S15-S19.
- Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. 1999. Phylogenetic perspectives in

innate immunity. *Science* 284:1313-1318.

Hoher M, Wohrle J, Wohlfrom M, Kamenz J, Nusser T, Grebe OC, Hanke H, Kochs M, Reske SN, Hombach V, Kotzerke J. 2003. Intracoronary β -irradiation with a rhenium-188-filled balloon catheter: a randomized trial in patients with de novo and restenotic lesions. *Circulation* 107:3022-3027.

Hutchinson F. 1985. Chemical changes induced in DNA by IR. *Prog Nucleic Acid Res Mol Biol* 32:115-154.

Huxford T, Huang DB, Malek S, Ghosh G. 1998. The crystal structure of the p50/p65 complex reveals mechanisms of NF- κ B inactivation. *Cell* 95:759-770.

Iademerco MF, McQuillan JJ, Rosen GD, Dean DC. 1992. Characterization of the promoter for VCAM-1. *J Biol Chem* 267:16323-16329.

Kachel R. 1996. Results of balloon angioplasty in the carotid arteries. *J Endovasc Surg* 3:22-30.

Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. *Science* 284:657-661.

Karin M, Smeal T. 1992. Control of transcription factors by signal transduction pathways: the beginning of the end. *Trends Biochem Sci* 17:418-422.

Karin M. 1995. The regulation of AP-1 activity by MAPKs. *J Biol Chem* 270:16483-16486.

Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF- κ B activity. *Annu Rev Immunol* 18:621-663.

Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R. 1996. Low molecular weight heparin (reviparin) in PTCA. Results of a randomised, double blind,

unfractionated Fheparin and placebo-controlled, multicentre trial (REDUCE Trial). J Am Coll Cardiol 28:1437-1443.

Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16:7054-7066.

Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH. 2000. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother Oncol 54:273-282.

Kerppola TK, CurranT. 1995. Transcription. Zen and the art of Fos and Jun. Nature 373:199-200.

King SB 3rd, Schlumpf M. 1993. Ten-year completed follow-up of PTCA: the early Zurich experience. J Am Coll Cardiol 22: 353-360.

Kotani M, Fukuda N, Ando H, Hu WY, Kunimoto S, Saito S, Kanmatsuse K. 2003. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc Res 57:265-276.

Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. 2001. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NF- κ B activation without interfering with the I κ B degradation pathway. J Biol Chem 276:11402-11408.

Lauri D, Martin-Padura I, Biondelli T, Rossi G, Bernasconi S, Giavazzi R, Passerini F, Van Hinsbergh V, Dejana E. 1991. Role of β_1 integrins in tumor cell adhesion to cultured human endothelial cells. Lab Invest 65:525-531.

Lawrence R, Chang LJ, Siebenlist U, Bressler P, Sonenshein GE. 1994. VSMCs express a constitutive NF- κ B-like activity. J Biol Chem 269:28913-28918.

Lee C, Schwartz MP, Prakash S, Iwakura M, Matouschek A. 2001. ATP-dependent proteases

degrade their substrates by processively unraveling them from the degradation signal. Mol Cell 7:627-637.

Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Ellis S, Holmes DR, Kerieakes D, Kuntz RE. 2001. Localized intracoronary γ -radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344:250-256.

Lewis M, Amento EP, Unemori EN. 1999. Transcriptional inhibition of stromelysin by interferon- γ in normal human fibroblasts is mediated by the AP-1 domain. J Cell Biochem 72:373-386.

Li N, Karin M. 1998. IR and short wavelength UV activate NF- κ B through two distinct mechanisms. Proc Natl Acad Sci USA 95:13012-13017.

Li X, Stark GR. 2002. NF- κ B-dependent signaling pathways. Exp Hematol 30:285-296.

Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.

Lichter AS, Lawrence TS. 1995. Recent advances in radiation oncology. N Engl J Med 332:371-379.

Lim VY, Lim YL. 2003 Restenosis in percutaneous coronary intervention--is drug-eluting stent the answer? Singapore Med J 44:482-487.

Lin L, Ghosh S. 1996. A glycine-rich region in NF- κ B p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 16:2248-2254.

Lin L, DeMartino GN, Greene WC. 1998. Cotranslational biogenesis of NF- κ B p50 by the 26S proteasome. Cell 92:819-829.

Lin L, DeMartino GN, Greene WC. 2000. Cotranslational dimerization of the Rel homology domain of NF- κ B1 generates p50-p105 heterodimers and is required for effective p50 production. EMBO J 19:4712-4722.

Liu X, Huang Y, Hanet C, Vandormael M, Legrand V, Dens J, Vandenbossche JL, Missault L, Vrints C, De Scheerder I. 2003. Study of antirestenosis with the BiodivYsio

dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. *Catheter Cardiovasc Interv* 60:172-178.

Macleod K, Leprince D, Stehelin D. 1992. The ets gene family. *Trends Biochem Sci* 17:251-256.

Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. 2000. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. *Mol Cell Biol* 20:1626-1638.

Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IKK and activation of the MAPK p38. *J Biol Chem* 276:18934-18940.

Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Monici Preti PA, Repetto S, De Servi S. 1994. Trapidil (triazolopyrimidine), a PDGF antagonist, reduces restenosis after PTCA. Results of the randomised double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. *Circulation* 90:2710-2715.

Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. 1993. VCAM-1 gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. *J Clin Invest* 92:1866-1874.

McBride K, Nemer M. 1998. The C-terminal domain of c-Fos is required for activation of an AP-1 site specific for Jun-Fos heterodimers. *Mol Cell Biol* 18:5073-5081.

Mercurio F, Didonato J, Rosette C, Karin M. 1992. Molecular cloning and characterization of a novel Rel/NF-κB family member displaying structural and functional homology to NF-κB p50/p105. *DNA Cell Biol* 11:523-537.

Mercurio F, DiDonato JA, Rosette C, Karin M. 1993. p105 and p98 precursor proteins play an

active role in NF-κB-mediated signal transduction. *Genes Dev* 7:705-718.

Mintz GS, Kent KM, Pichard AD, Popma JJ, Satler LF, Leon MB. 1997a. IVUS insights into mechanisms of stenosis formation and restenosis. *Cardiol Clin* 15:17-29.

Mintz GS, Kent KM, Pichard AD, Satler LF, Popma JJ, Leon MB. 1997b. Contribution of inadequate arterial remodeling to the development of focal coronary artery stenosis. An IVUS study. *Circulation* 95:1791-1798.

Mohan N, Meltz ML. 1994. Induction of NF-κB after low-dose IR involves a reactive oxygen intermediate signaling pathway. *Radiat Res* 140:97-104.

Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaipler NJ, Firestein GS. 1992. $\alpha_4\beta_1$ integrin (VLA-4) ligands in arthritis. VCMA-1 expression in synovium and on fibroblast-like synoviocytes. *J Immunol* 149:1424-1431.

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 346:1773-1780.

Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T. 1997. In vivo transfection of cis element "decoy" against NF-κB binding site prevents myocardial infarction. *Nat Med* 3: 894-899.

Moses JW, Kipshidze N, Leon MB. 2002. Perspectives of drug-eluting stents: the next revolution. *Am J Cardiovasc Drugs* 2:163-172.

Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. 2002. IL1- β inhibits expression of p21 (WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to PDGF-BB in smooth muscle cells. *Arterioscler Thromb Vasc Biol* 22:1293-1298.

Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. 1992. Functional analysis of the

- human VSMC-1 promoter. *J Exp Med* 176:1583-1593.
- Neish AS, Read MA, Thanos D, Pine R, Maniatis T, Collins T. 1995. Endothelial IRF-1 cooperates with NF- κ B as a transcriptional activator of VCAM-1. *Mol Cell Biol* 15:2558-2569.
- Nilsson J, Sjolund M, Palmberg L, Thyberg J, Hedin CH. 1985. Arterial SMCs in primary culture produce a PDGF-like protein. *Proc Natl Acad Sci USA* 82:4418-4422.
- Norton J, Sloane JP, al-Saffar N, Haskard DO. 1992. Expression of adhesion molecules in human intestinal graft vs. host disease. *Clin Exp Immunol* 87:231-236.
- O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, Kimura T, Nobuyoshi M, Mizgala H, Purchio A, Schwartz SM. 1996. Betaig-h3, a TGF- β inducible gene is overexpressed in atherosclerotic and restenotic human vascular lesions. *Arterioscl Thromb Vasc Biol* 16:576-584.
- O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD. 1993. VCAM-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. *J Clin Invest* 92:945-951.
- O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. 1996. Neovascular expression of E-selectin, ICAM-1, and VCAM-1 in human atherosclerosis and their relation to intimal leukocyte content. *Circulation* 93:672-682.
- Okada Y, Saika S, Hashizume N, Kobata S, Yamanaka O, Ohnishi Y, Senba E. 1996. Expression of Fos family and Jun family proto-oncogenes during corneal epithelial wound healing. *Curr Eye Res* 15:824-832.
- Orian A, Schwartz AL, Israel A, Whiteside S, Kahana C, Ciechanover A. 1999. Structural motifs involved in ubiquitin-mediated processing of the NF- κ B precursor p105: roles of the GRR and a downstream ubiquitination domain. *Mol Cell Biol* 19:3664-3673.

Pahl HL. 1999. Activators and target genes of Rel/NF-κB transcription factors. *Oncogene* 18:6853-6866.

Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. 2003. A paclitaxel-eluting stent for the prevention of coronary restenosis. *N Engl J Med* 348:1537-1545.

Park SW, Hong MK, Moon DH, Oh SJ, Lee CW, Kim JJ, Park SJ. 2001. Treatment of diffuse in-stent restenosis with rotational atherectomy followed by radiation therapy with a rhenium-188-mercaptoproacetyltriglycine-filled balloon. *J Am Coll Cardiol* 38:631-637.

Pavlides GS. 2002. Brachytherapy for treatment of restenosis after percutaneous coronary intervention. *Hellenic J Cardiol* 43:216-218.

Pelletier RP, Ohye RG, Vanbuskirk A, Sedmak DD, Kincade P, Ferguson RM, Orosz CG. 1992. Importance of endothelial VCAM-1 for inflammatory leukocytic infiltration in vivo. *J Immunol* 149:2473-2481.

Peng HB, Libby P, Liao JK. 1995. Induction and stabilization of I κ B α by nitric oxide mediates inhibition of NF-κB. *J Biol Chem* 270:14214-14219.

Popovici C, Leveugle M, Birnbaum D, Coulier F. 2001. Coparalogy: physical and functional clusterings in the human genome. *Biochem Biophys Res Commun* 288:362-370.

Prasad AV, Mohan N, Chandrasekar B, Meltz ML. 1994. Activation of NF-κB in human lymphoblastoid cells by low-dose IR. *Radiat Res* 138:367-372.

Printseva OYu, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1. 1992. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. *Am J Pathol* 140:889-896.

Rajagopal V, Rockson SG. 2003. Coronary restenosis: a review of mechanisms and

management. Am J Med 115:547-553.

Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V, Palombella VJ. 2000. Nedd-8 modification of cul-1 activates SCF (β (TrCP))-dependent ubiquitination of I κ B α . Mol Cell Biol 20:2326-2333.

Rhodes LE, Joyce M, West DC, Strickland I, Friedmann PS. 1996. Comparison of changes in endothelial adhesion molecule expression following UVB irradiation of skin and a human dermal microvascular cell line (HMEC-1). Photodermatol Photoimmunol Photomed 12:114-121.

Rice GE, Munro JM, Corless C, Bevilacqua MP. 1991. Vascular and nonvascular expression of INCAM-110: a target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 138:385-393.

Rice NR, MacKichan ML, Israel A. 1992. The precursor of NF- κ B p50 has I κ B-like functions. Cell 71:243-253.

Rodel F, Schaller U, Schultze-Mosgau S, Beuscher HU, Keilholz L, Herrmann M, Voll R, Sauer R, Hildebrandt G. 2004. The induction of TGF- β 1 and NF- κ B parallels a biphasic time course of leukocyte/endothelial cell adhesion following low-dose X-irradiation. Strahlenther Onkol 180:194-200.

Rosen GD, Sanes JR, LaChance R, Cunningham JM, Roman J, Dean DC. 1992. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell 69:1107-1119.

Ross R. 1999. Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126.

Sabate M, Kay IP, van Der Giessen WJ, Cequier A, Ligthart JM, Gomez-Hospital JA, Carlier SG, Coen VL, Marijnissen JP, Wardeh AJ, Levendag PC, Serruys PW. 1999a. Preserved endothelium-dependent vasodilation in coronary segments previously treated with balloon angioplasty and intracoronary irradiation. Circulation 100:1623-1629.

Sabate M, Serruys PW, van der Giessen WJ, Ligthart JM, Coen VL, Kay IP, Gijzel AL,

Wardeh AJ, den Boer A, Levendag PC. 1999b. Geometric vascular remodeling after balloon angioplasty and β -radiation therapy: a three-dimensional IVUS study. Circulation 100:1182-1188.

Sabate M, Costa MA, Kozuma K, Kay IP, van der Giessen WJ, Coen VL, Ligthart JM, Serrano P, Levendag PC, Serruys PW. 2000. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation 101:2467-2471.

Sangiorgi G, Taylor AJ, Farb A, Carter AJ, Edwards WD, Holmes DR, Schwartz RS, Virmani R. 1999. Histopathology of post-PTCA remodeling in human coronary arteries. Am Heart J 138:681-687.

Schena M, Shalon D, Davis RW, Brown PO. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470.

Schwartz L, Lesperance J, Bourassa MG, Eastwood C, Kazim F, Arafah M, Ganassin L. 1990. The role of antiplatelet agents in modifying the extent of restenosis following PTCA. Am Heart J 119:232-236.

Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR Jr. 1998. Artery size, neointima, and remodeling: time for some standards. J Am Coll Cardiol 32:2087-2094.

Sen CK, Packer L. 1996. Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720.

Sen R, Baltimore D. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-716.

Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. 1991. Prevention of restenosis after PTCA with thromboxane A2-receptor blockade. Circulation 84:1568-1580.

Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H. 1993. Evaluation of ketanserin in the prevention of


restenosis after PTCA. *Circulation* 88:1588-1601.

Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med* 331:489-495.

Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. 2000. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. *Cell* 103:897-907.

Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovacs I, Watkins SC, Tzeng E. 1998. Efficient inhibition of intimal hyperplasia by adenovirus-mediated iNOS gene transfer to rats and pigs *in vivo*. *J Am Coll Surg* 187:295-306.

Shiffman D, Mikita T, Tai JT, Wade DP, Porter JG, Seilhamer JJ, Somogyi R, Liang S, Lawn RM. 2000. Large-scale gene expression analysis of cholesterol-loaded macrophages. *J Biol Chem* 275:37324-37332.




Shimizu N, Suzuki H, Wakabayashi K, Iso Y, Shibata M, Yorozuya M, Katagiri T, Takeyama Y. 2004. Expression of ICAM-1 and VCAM-1 in the pig coronary artery injury model: comparison of plain old balloon angioplasty and stent implantation. *J Cardiol* 43:131-139.

Siebenlist U, Franzoso G, Brown K. 1994. Structure, regulation and function of NF-κB. *Annu Rev Cell Biol* 10:405-455.

Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. 1987. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 316:701-706.

Sigwart U. 1999. Prevention of restenosis after stenting. *The Lancet* 354:269-270.

- Sigwart U, Prasad S, Radke P, Nadra I. 2001. Stent coatings. *J Invasive Cardiol* 13:141-142.
- Silverman N, Maniatis T. 2001. NF- κ B signaling pathways in mammalian and insect innate immunity. *Genes Dev* 15:2321-2342.
- Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM. 1992. VCAM-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. *Blood* 80:388-395.
- Singh N, Sun Y, Nakamura K, Smith MR, Colburn NH. 1995. c-Jun/AP-1 as possible mediators of TNF- α -induced apoptotic response in mouse JB6 tumor cells. *Oncology Res* 7:353-362.
- Sivamurthy N, Stone DH, Logerfo FW, Quist WC. 2001. Apo J inhibits the migration, adhesion, and proliferation of VSMCs. *J Vasc Surg* 34:716-723.
- Sizemore N, Leung S, Stark GR. 1999. Activation of PI3K in response to IL-1 leads to phosphorylation and activation of the NF- κ B p65/RelA subunit. *Mol Cell Biol* 19:4798-4805.
- Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. 1989. Cooperative interactions of LFA-1 and MAC-1 with ICAM-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. *J Clin Invest* 83:2008-2017.
- Smyth GK, Yang YH, Speed T. 2003. Statistical issues in cDNA microarray data analysis. *Methods Mol Biol* 224:111-136.
- Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. 2001. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and IVUS followup. *Circulation* 104:2007-2011.
- Springer TA. 1990. Adhesion receptors of the immune system. *Nature* 346:425-434.
- Staunton DE, Dustin ML, Erickson HP, Springer TA. 1990. The arrangement of the Ig-like

- domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. *Cell* 61:243-254.
- Stankovic G, Orlic D, Di Mario C, Corvaja N, Airoldi F, Chieffo A, Amato A, Orecchia R, Colombo A. 2003. β -radiation therapy for long lesions in native coronary vessels: a matched comparison between de novo and in-stent restenotic lesions. *Cardiovasc Radiat Med* 4:18-24.
- Still IH, Vince P, Cowell JK. 1999. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. *Genomics* 58:165-170.
- Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, Logan RA, Mehta SR, Levy DE, Ezrin AM, Keeley FW. 1996. In vivo collagen turnover following experimental balloon angioplasty injury and the role of MMP. *Circ Res* 79:541-550.
- Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M. 2000. Decoy against NF- κ B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. *Gene Ther* 7:1847-1852.
- 
- Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Lighart JM, Disco C, Backx B, Russell ME. 2003. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. *Circulation* 107:559-564.
- Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, Munzel T, Belardi J, Ruzylo W, Bilodeau L, Kelbaek H, Ormiston J, Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME, Colombo A. 2004. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial IVUS analyses: data from the randomized TAXUS-II trial. *Circulation* 109:196-200.
- Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, Libby P. 1993.

Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury.

Circulation 88:1788-1803.

Taylor AJ, Gorman PD, Farb A, Hoopes TG, Virmani R. 1999. Long-term coronary vascular response to ^{32}P β -particle-emitting stents in a canine model. Circulation 100:2366-2372.

Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. 1995. I κ B β regulates the persistent response in a biphasic activation of NF- κ B. Cell 80:573-582.

Topper JN, Cai J, Falb D, Gimbrone MA Jr. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell NOS are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422.

Treina G, Scaletta C, Fourtanier A, Seite S, Frenk E, Applegate LA. 1996. Expression of ICAM-1 in UVA-irradiated human skin cells in vitro and in vivo. Br J Dermatol 135:241-247.

Turner R, Tjian R. 1989. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science 243:1689-1694.

Utans U, Arceci RJ, Yamashita Y, Russell ME. 1995. Cloning and characterization of AIF-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 95:2954-2962.

Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G, Thomas M, Calman F, Disco C, Serruys PW, Wijns W, Dose-Finding Study Group. 2001. Endoluminal β -radiation therapy for the prevention of coronary restenosis after balloon angioplasty. N Engl J Med 344:243-249.

Vodovotz Y, Waksman R, Kim WH, Bhargava B, Chan RC, Leon M. 1999. Effects of intracoronary radiation on thrombosis after balloon overstretch injury in the porcine model. Circulation 100:2527-2533.

- Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB III. 1995. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine: a possible role for radiation therapy in restenosis prevention. *Circulation* 91:1533-1539.
- Waksman R. 1999. Late thrombosis after radiation. Sitting on a time bomb. *Circulation* 100:780-782.
- Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, Satler LF, Mehran R, Serruys PW, Lansky AJ, Fitzgerald P, Bhargava B, Kent KM, Pichard AD, Leon MB. 2000. Intracoronary γ -radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. *Circulation* 101:2165-2171.
- Waksman R, Cheneau E, Ajani AE, White RL, Pinnow E, Torguson R, Deible R, Satler LF, Pichard AD, Kent KM, Teirstein PS, Lindsay J. 2003a. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenosis for long lesions (Long WRIST). *Circulation* 107:1744-1749.
- Waksman R, Raizner A, Popma JJ. 2003b. β emitter systems and results from clinical trials. state of the art. *Cardiovasc Radiat Med* 4:54-63.
- Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. 2003c. Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. *Lancet* 359:551-557.
- Waller BF, Johnson DE, Schnitt SJ, Pinkerton CA, Simpson JB, Baim DS. 1993. Histologic analysis of directional coronary atherectomy samples. A review of findings and their clinical relevance. *Am J Cardiol* 72:80E-87E.
- Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. 1996. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. *J Am Coll Cardiol* 28:1573-1579.

- Wang D, Baldwin AS Jr. 1998. Activation of NF-κB-dependent transcription by TNF-α is mediated through phosphorylation of RelA/p65 on Ser 529. *J Biol Chem* 273:29411-29416.
- Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. 2000. TNF-α-induced phosphorylation of RelA/p65 on Ser 529 is controlled by CKII. *J Biol Chem* 275:32592-32597.
- Wang WW, Howells RD. 1994. Sequence of the 5'-flanking region of the rat c-Fos proto-oncogene. *Gene* 143:261-264.
- Ward JF. 1990. The yield of DNA double-strand breaks produced intracellularly by IR: a review. *Int J Radiat Biol* 57:1141-1150.
- Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J. 1995. Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: persistent benefit at 6-month follow-up. *J Am Coll Cardiol* 25:1451-1456.
- Williams ES, Miller JM. 2002. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. *J Am Coll Cardiol* 40:1-18.
- 
- Xanthoudakis S, Miao GG, Curran T. 1994. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. *Proc Natl Acad Sci USA* 91:23-27.
- Xanthoudakis S, Curran, T. 1996. Redox regulation of AP-1: a link between transcription factor signaling and DNA repair. *Adv Exp Med Biol* 387:69-75.
- Yamawaki M, Futamura S, Horio T. 1996. UVB radiation suppresses the TNF-α-induced expression of E-selectin and ICAM-1 on cultured human umbilical vein endothelial cells. *Dermatol Sci* 13:11-17.
- Yasukawa H, Imaizumi T, Matsuoka H, Nakashima A, Morimatsu M. 1997. Inhibition of intimal hyperplasia after balloon injury by antibodies to ICAM-1 and LFA-1. *Circulation* 95:1515-1522.
- Yates S, Rayner TE. 2002. Transcription factor activation in response to cutaneous injury:

role of AP-1 in reepithelialization. *Wound Repair Regen* 2002;10:5-15.

Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha_4\beta_1$ integrin. *Nature* 356:63-66.

Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T. 2001. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of NF- κ B binding site as a novel molecular strategy. *Gene Ther* 8:1635-1642.

Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. 1997. The transcriptional activity of NF- κ B is regulated by the I κ B-associated PKAc subunit through a cyclic AMP-independent mechanism. *Cell* 89:413-424.

Zhou D, Brown SA, Yu T, Chen G, Barve S, Kang BC, Thompson JS. 1999. A high dose of IR induces tissue-specific activation of NF- κ B in vivo. *Radiat Res* 151:703-709.

Zibara K, Bourdillon MC, Chignier E, Covacho C, McGregor JL. 1999. Identification and cloning of a new gene (2A3-2), homologous to human translational elongation factor, upregulated in a proliferating rat smooth muscle cell line and in carotid hyperplasia. *Arterioscler Thromb Vasc Biol* 19:1650-1657.

Zubakov D, Hoheisel JD, Kluxen FW, Brandle M, Ehring T, Hentsch B, Frohme M. 2003. Late ischemic preconditioning of the myocardium alters the expression of genes involved in inflammatory response. *FEBS Lett* 547:51-55.